Precision Reagents for Monogenic Obesity Research & Melanocortin Pathway Validation
As the central precursor to α-MSH and ACTH, POMC represents a critical node in metabolic regulation. With the approval of MC4R-targeting therapies for POMC deficiency syndromes, research focus has shifted toward direct pathway modulation, gene replacement strategies, and processing enzyme modulation. TarMart provides sequence-verified, endotoxin-controlled POMC antigens and pathway tools to support quantitative bioanalytical assay development. Key genetic variations associated with POMC deficiency include dbSNP:rs139750421, rs28932471, and rs750136455.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for POMC pathway drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | POMC Full-Length Recombinant Protein HEK293 expressed, >95% purity, Endotoxin <1 EU/µg. Includes pro-peptide and cleavage sites. Sequence Verified. |
View POMC Products |
| Processed Fragments | ACTH (1-39) & α-MSH Bioactive Peptides Synthetic/Recombinant standards for quantitative assays. Mass Spec verified. |
View POMC Products |
| Gene Delivery | POMC-ORF Lentivirus Neuron-specific expression for hypothalamic cell models. Full-length ORF with native signal peptide. |
View POMC Products |
| Benchmark Ab | Anti-POMC (Recombinant) Positive control for detection and immunogenicity assessment. |
View POMC Products |
| Validator | POMC siRNA Set For knockdown verification in metabolic disease models. |
View POMC Products |
| Downstream Target | MC4R (Melanocortin-4 Receptor) Critical effector for POMC-derived peptides. GPCR stable cell line support. |
View MC4R Products |
| Pathway Partner | LEPR (Leptin Receptor) Upstream regulator of POMC neurons. Synergistic pathway analysis. |
View LEPR Products |
| Processing Enzyme | PCSK1 (Prohormone Convertase 1) Essential for POMC maturation. Mutant variants for processing-deficiency models. |
View PCSK1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Full-length vs. Processed Form Discrimination | Purified full-length POMC (1-267) and defined cleavage fragments (ACTH, MSH) available as separate calibrated standards |
| Hypothalamic Neuronal Expression | POMC Lentivirus particles for stable integration in NPY/AgRP neuronal lineage studies |
| Cross-species Translation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ortholog proteins with sequence-verified conservation at cleavage sites |
| Processing-Deficiency Mutant Analysis | PCSK1 mutant recombinant proteins and POMC cleavage-resistant variants for mechanistic studies |
| Congenital deficiency mutation modeling | Site-directed POMC Mutant Panel targeting key mutations (rs139750421, rs28932471, rs750136455) for functional loss-of-function assays; strictly verified by mass spec |
Live POMC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials for POMC Deficiency
- ➤ Latest Gene Therapy Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic landscape for POMC-related disorders is transitioning from symptomatic treatment to precision genetic intervention. Rhythm Pharmaceuticals' Setmelanotide (Imcivree), an MC4R agonist, has established proof-of-concept for targeting downstream of POMC deficiency, yet the field is rapidly advancing toward direct POMC neuronal repair via AAV-mediated gene therapy. Preclinical programs are investigating hypothalamic-targeted delivery vectors to restore endogenous α-MSH production rather than chronic peptide replacement. The next wave of R&D focuses on processing enzyme modulation (PCSK1/PCSK2 activators) to rescue partial POMC deficiency and combination approaches with leptin sensitization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV-POMC) | Academic Consortia, Early Biotech | POMC Deficiency Obesity | POMC Lentivirus for transduction efficiency validation; Full-length protein as transgene expression standard |
| MC4R Peptide Agonists | Rhythm Pharmaceuticals | POMC/LEPR Deficiency | α-MSH bioactive peptide standard; MC4R binding assays |
| Processing Enzyme Modulators | Preclinical Programs | Obesity, Diabetes | PCSK1 mutant proteins; POMC processing assays |
| AgRP/MC4R Antagonists | Novartis, Academic Labs | Cancer Cachexia | AgRP recombinant protein; Competitive binding assays |
| Small Molecule (POMC Modulator) | Discovery-Stage Pharma | Obesity, Metabolic Syndrome | Full-length & Mutant POMC Protein for biochemical and processing assays |
Key Genetic Variations
POMC deficiency is associated with several documented missense mutations that impair protein processing or receptor activation. Based on UniProt (P01189), key verified mutations include:
- dbSNP:rs139750421 (UniProt VAR_010700)
- dbSNP:rs28932471 (UniProt VAR_029762)
- dbSNP:rs750136455 (UniProt VAR_010715)
These variants are critical for developing accurate disease models and functional assays. TarMart offers a site-directed POMC Mutant Panel covering these variants for loss-of-function studies.